Value of pulse pressure as a cardiovascular risk marker;Valor de la presión de pulso como marcador de riesgo cardiovascular

Medicina Clinica

Volumn 126, Issue 10, 2006, Pages 384-388

  De La Sierra, Alejandro ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Arterial stiffness; Cardiovascular disease; Isolated systolic hypertension; Pulse pressure; Taget organ damage

Indexed keywords

ANTIHYPERTENSIVE AGENT;

AORTA; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ELASTICITY; HUMAN; HYPERTENSION; LIFESTYLE; MORBIDITY; MORTALITY; OBESITY; ORGAN PERFUSION; PULSE PRESSURE;

EID: 33646345858     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13086050     Document Type: Review

References (41)

1. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:1003-10.
2. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-74.
3. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-38.
4. Kannel WB, Wolf PA, McGee DL, Dawber TR, McNamara P, Castelli WP. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. JAMA. 1981;245:1225-9.
5. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356-62.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint national Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-72.
7. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
8. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601-10.
9. Madhaven S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension. 1994;23:395-401.
10. Benetos A, Safar M, Rudnichi A, Smuylan H, Richard JL, Ducimetière P, et al. Pulse pressure: a predictor of long-term mortality in a french male population. Hypertension. 1997;30:1410-5.
11. Benetos A, Rudnichi A, Safar M, Guize L. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension. 1998;32:560-4.
12. Alderman M, Cohen H, Madhaven S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. J Hypertens. 1998;16:761-9.
13. Chae CU, Pfeffer MA, Glynn RJ, Mitchell GF, Taylor JO, Hennekens CH. Increased pulse pressure and risk of heart failure in the elderly. JAMA. 1999;281:634-9.
14. Halder AW, Larson MG, Franklin SS, Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Study. Ann Intern Med. 2003;138:10-6.
15. Klag MJ, Brancati FL, Whelton PK, Randall BL, Neaton JD, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-8.
16. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful for predicting coronary heart disease? The Framingham Study. Circulation. 1999;100:354-60.
17. De la Sierra A, Bové A, Sierra C, Bragulat E, Gómez- Angelats E, Antonio MT, et al. Impacto de los componentes y sistema de medición de la presion arterial sobre la lesión de órgano diana y las complicaciones cardiovasculares en la hipertensión arterial. Med Clin (Barc). 2002;119:125-9.
18. Miura K, Dyer AR, Greenland P, Daviglus ML, Hill MA, Liu K, et al. Pulse pressure compared with other blood pressure indexes in the prediction of 25-year cardiovascular and all-cause mortality. Hypertension. 2001;38:232-7.
19. Domanski MJ, Mitchell G, Pfeffer M, Neaton JD, Norman J, Svendsen K, et al. Pulse pressure and cardiovascular disease-related mortality. Follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 2002;287:2677-83.
20. Vaccarino V, Bergr A, Abramson J, Black H, Setaro J, Davey J, et al. Pulse pressure and risk of cardiovascular events in the systolic hypertension in the elderly program. Am J Cardiol. 2001;88:980-6.
21. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palú C, et al. Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. J Hypertens. 1998;16:949-61.
22. Sutton-Tyrrell K, Alcorm HG, Wolfson SK, Kelsey SF,1 Kuller LH. Predictors of carotid stenosis in older adults with and without isolated systolic hypertension. Stroke. 1993;24:355-61.
23. Pannier B, Brunel P, Aroussy WE, Lacolley P,1 Safar ME. Pulse pressure and echocardiographic findings in essential hypertension. J Hypertens. 1989;7:127-32.
24. Franklin SS, Gustin W, Wong ND, Larson MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-related changes in blood pressure. Circulation. 1997;96:308-15.
25. London GM, Guerin AP. Influence of arterial pulse and reflected waves on blood pressure and cardiac function. Am Heart J. 1999;138:220-4.
26. Safar ME, London GM, Asmar R, Frohlich ED. Recent advances on large arteries in hypertension. Hypertension. 1998;32:156-61.
27. O'Rourke MF. Mechanical principles in arterial disease. Hypertension. 1995;26:2-9.
28. O'Rourke MF, Staessen JA. Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens. 2002;15:426-44.
29. Safar ME, Boudier HS. Vascular development, pulse pressure, and the mechanisms of hypertension. Hypertension. 2005;46:205-9.
30. Kwagyan J, Tabe CE, Xu S, Maqbool AR, Gordeuk VR, Randall OS. The impact of body mass index on pulse pressure in obesity. J Hypertens. 2005;23:619-24.
31. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-64.
32. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-64.
33. Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo for older patients with isolated systolic hypertension. J Hypertens. 1998;16:1823-9.
34. Staessen JA, Gasowski J, Wang JG, Thijs L, Hond ED, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865-72.
35. Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, et al, for the LIFE Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartan Intervention For Endpoint Reduction (LIFE) Substudy. JAMA. 2002;288:1491-8.
36. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al, for the Department of Veterans Affairs Cooperative Study Group on Antinypertensive Agents. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914-21.
37. Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al, for the Treatment of Mild Hypertension Study. Treatment of mild hypertension study: final results. JAMA. 1993;270:713-24.
38. Cushman WC, Materson BJ, Williams DW, Reda DJ, for the Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Hypertension. 2001;38:953-7.
39. De la Sierra A, Artés M, López JS, Arcos E, Muñoz A, en representación de los investigadores del estudio ETAPA. Efecto del tratamiento antihipertensivo sobre la presion de pulso. Med Clin (Barc). 2002;119:41-5.
40. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlortalidone. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-75.
41. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97.